Kornimate/medical-research-clean huggingface dataset:
effectiveness of non-invasive vagus nerve stimulation as an adjuvant treatment in patients with sepsis in intensive care.

Conditions: Sepsis; Septic Shock

Summary: sepsis is one of the leading causes of death in intensive care. about 50% of patients with septic shock die after 1 year; and 50% of survivors suffer from cognitive decline. the pathophysiological mechanisms of serious complications of sepsis are now well known. in fact, the systemic inflammation related to sepsis amplifies the release of pro-inflammatory cytokines and neurotoxic mediators, hence an increase in deleterious phenomena such as oxidative stress, mitochondrial dysfunction, endothelial activation, disruption of the blood-brain barrier, neuroinflammation (astrocytic and microglial activation) leading to multi-organ failure which compromises the patient's vital and functional prognosis. although there has been progress in the understanding of its pathophysiology, the management of sepsis and septic shock in intensive care relies mainly on anti-infective treatments and the restoration of cardiovascular and respiratory functions. there is virtually no adjuvant therapy for the management of sepsis, apart from a few hormonal therapies such as insulin to maintain blood glucose levels below 180 mg / dl and low doses of corticosteroids and vasopressin. there is therefore a pressing need to develop innovative treatments targeting inflammatory and immunological processes in order to reduce the complications of sepsis and improve patient prognosis. some recent work has shown that electrical vagus nerve stimulation (snv), a technique used for the treatment of drug-resistant epilepsy, can modulate inflammatory and immune responses and control inflammation syndrome in animal models of sepsis, arthritis and rheumatism in humans. in this pilot study the investigators plan to evaluate the efficacy of transcutaneous (non-invasive) snv as an adjuvant treatment in patients with sepsis in intensive care.


Eligibility criteria:
inclusion criteria: * age\> 18 years old * adult man or woman, hospitalized in intensive care, presenting with sepsis for at least 24 hours according to the diagnostic criteria (singer et al., 2016). * informed consent signed by patient or family member/trusted support person * in an emergency situation, in the absence of family members/trusted family/trusted support person exclusion criteria: * patient under guardianship or curatorship * patient in a severe state of agitation. * patient in a state of brain death or active limitation of treatment. * multiple trauma patient, with multiple fractures of the skull. * refusal to participate in the study or to sign the informed consent by the patient or his loved one, * pregnant or breastfeeding woman, * no affiliation to a social security scheme. * patient with cochlear implant * patient with heart disease * patient with asthma
safety and efficacy study of jv-gl1 in patients with open-angle glaucoma or ocular hypertension

Conditions: Ocular Hypertension; Open Angle Glaucoma

Summary: the aim of this research study is to assess the safety and feasibility of lowering intraocular pressure (iop) using an experimental study drug, jv-gl1.

this is an open-label, dose escalation and dose expansion, study in adult participants with open-angle glaucoma or ocular hypertension. the study is divided into 2 parts: part 1 of the study is a dose escalation, sequentially testing escalating doses of jv-gl1. part 2 of the study will be randomized 2:2:1 (experimental dose a: experimental dose b: active control), treating additional subjects at the selected jv-gl1 doses or latanoprost for 28 days.

Eligibility criteria:
inclusion criteria: * bilateral open-angle glaucoma or ocular hypertension exclusion criteria: -

Keywords: open angle glaucoma ocular hypertension
triple versus quadruple therapy for the eradication of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: the study aimed to compare the efficacy and safety of 7-day and 14-day vonoprazan-amoxicillin-tetracycline triple therapy with 14-day vonoprazan-amoxicillin-tetracycline-bismuth quadruple therapy for the eradication of helicobacter pylori. subjects were randomized to receive the intervention and were reviewed by 13c-urea breath test after 6 weeks. the eradication rates, adverse reaction rates and patient adherence were calculated.

h. pylori-positive patients without eradication history were recruited according to inclusion and exclusion criteria and randomized to the intervention: 14-day quadruple regimen: vonoprazan 20mg bid + amoxicillin 1000mg bid + tetracycline 500mg qid + bismuth 220mg bid for 14 days 14-day triple regimen: vonoprazan 20mg bid + amoxicillin 1000mg bid + tetracycline 500mg qid 14 days 7-day triple regimen: vonoprazan 20mg bid + amoxicillin 1000mg bid + tetracycline 500mg qid 7 days subjects were asked to record adverse events and 6 weeks after treatment, 13c-urea breath test was tested for confirmation. the eradication rates, adverse reaction rates and patient adherence were calculated and analysed, and the results were analysed to provide more information for eradication regimens of h. pylori.

Eligibility criteria:
inclusion criteria: 1. patients aged 18-70 years old; 2. patients with h.pylori infection (positive rapid urease test, 13c/14c-urea breath test); 3. patients without previous treatment for h. pylori eradication. exclusion criteria: 1. patients with serious underlying diseases, such as liver insufficiency (aspartate aminotransferase or alanine aminotransferase greater than the normal value), renal insufficiency (cr≥2.0mg/dl or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%; 2. patients with active gastrointestinal bleeding; 3. patients with a history of upper gastrointestinal surgery; 4. patients allergic to treatment drugs; 5. patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitor within 2 weeks; 6. patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial; 7. patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse; 8. patients who are unwilling or incapable to provide informed consents.
a confirmatory study of tau-284 in pediatric patients with atopic dermatitis

Conditions: Dermatitis; Atopic

Summary: the objective of this study is to verify the non-inferiority of tau-284 to ketotifen fumarate dry syrup in the change in the severity of pruritus after the treatment period.

this is a randomized, double-blind, parallel-group comparative study to demonstrate the noninferiority of tau-284 to ketotifen fumarate in pediatric patients with atopic dermatitis, as assessed by the primary endpoint of the change from baseline in pruritus score after 2-week treatment with tau-284 (20 mg/day) or ketotifen fumarate dry syrup (2 g/day); and to investigate the safety, and plasma concentrations of tau-284.

Eligibility criteria:
inclusion criteria: * patients aged between 7 and 15 years * patients giving assent and whose legal guardian giving informed consent * outpatients * patients diagnosed as atopic dermatitis * patients who require the treatment with topical corticosteroid on areas other than face, head and neck * patients whose diaries can be properly maintained * patients who have 2 grades or more pruritus score exclusion criteria: * patients with bronchial asthma who require concomitant use of the corticosteroid * patients who have been undergoing specific desensitization therapy or nonspecific immunomodulation therapy or phototherapy * patients with current or previous history of drug hypersensitivity * patients who have been treated with bepotastine besilate in the past * patients who have; a skin infection, or with zooparasite such as scabies and pediculosis; eczematous otitis externa with perforation in the eardrum; dermal ulcer, or profound heat burn or frostbite of the severity higher than the grade 2; on areas where topical corticosteroid is applied * patients who have spastic disease such as epilepsy * patients who concurrently have renal function abnormalities that may cause safety problems * patients who do not give consent to use birth control * pregnant patients, at risk of pregnancy or breastfeeding * patients who had participated in any clinical trial in the last 12 weeks
mechanism and efficacy of rehabilitation approaches

Conditions: Cerebrovascular Accidents

Summary: identify the possible mechanisms and the relative effectiveness of existing rehabilitation approaches that target upper extremity deficits of stroke patients on the ground that these approaches are based on neuroplasticity principles and sound motor control theories.

comparisons of constraint-induced therapy (cit) vs. bilateral arm training (bit)vs. combined therapy were made. stroke patients will receive one of these three approaches and be evaluated pre- and post-treatment. the treatment will last 3 weeks and 5 days per week. the evaluation will include clinical measures of motor function, adl, and quality of life, kinematic performance, and activation patterns of cortex.

Eligibility criteria:
inclusion criteria: * a first-ever clinical cerebrovascular accident patients * at least 6 months post-stroke onset * premorbid right-hand dominance * demonstration of brunnstrom stage iii of the affected upper extremity * no excessive spasticity in the joints of the affected upper extremity exclusion criteria: * a score of less than 24 on the mini mental state exam * poor physical conditions that would interfere with participation * excessive pain in any joint that might limit participation

Keywords: stroke rehabilitation cortical reorganization kinematic analysis
incidence of scln metastasis in patients referred for ebus-tbna

Conditions: Lung Cancer

Summary: evaluation of the anatomic extent of a primary lung cancer and presence of metastasis are essential for selection of an appropriate management strategy. endobronchial ultrasound transbronchial needle aspiration (ebus-tbna) is a reliable and established technique to evaluate involvement of mediastinal lymph nodes (ln); however, it is an invasive procedure and may not be tolerated in patients with severe underlying lung disease. one exception is the superficially located supraclavicular lymph nodes (scln), which can easily be biopsied with percutaneous us-guided-fine needle aspiration (us-fna). traditionally, this nodal group is evaluated by palpation; however, literature suggests that palpation itself fails to capture 66% of proven disease by cytology, which challenges the acceptance that non-palpable nodes are indicative of absent disease. since all palpable scln are biopsied to rule out metastasis, we may potentially up-stage more patients using ultrasound evaluation for non-palpable nodes; and offer more appropriate management. currently, the incidence for non-palpable scln metastasis has not been defined in this patient population presenting for ebus-tbna. the primary objective is to determine the incidence of supraclavicular lymph node metastasis by ultrasound evaluation in patients referred for ebus-tbna.


Eligibility criteria:
inclusion criteria: * all patients age 20yrs or greater referred for ebus-tbna with suspicion for primary lung cancer exclusion criteria: 1. refusal to sign consent 2. signs of skin infection along the neck 3. adults who lack the capacity to sign consent.

Keywords: interventional pulmonary ebus-tbna lung cancer staging
revised algorithm for next generation devilbiss healthcare autoadjust continuous positive airway pressure (cpap)

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this protocol is to improve the current fda-approved continuous positive pressure auto-titration algorithm, including treatment precision, residual disease detection characteristics and phenotyping with the devilbiss brand autoadjust cpap device.


Eligibility criteria:
inclusion criteria: * apnea hypopnea index ≥ 15 / hour of sleep on the diagnostic polysomnogram, or diagnostic component of a split night polysomnogram * sleep efficiency reported on cpap titration night psg should be \> 78% * diagnosis of moderate to severe obstructive sleep apnea (ahi ≥15) or central/complex sleep apnea * on stable cpap or apap \[automatic positive airway pressure\] therapy, with compliant use averaging 4 or more hours nightly * age 21-75 years * predominately central sleep apnea for up to 10 subjects only * willingness to give written informed consent and ability to adhere to visit schedule exclusion criteria: diagnosis of mild sleep apnea * cpap naïve patients * co-morbid conditions which render participation to be at risk. these may include patients with congestive heart failure, copd \[chronic obstructive pulmonary disease\] or psychiatric illness * allergies to mask materials * evidence of another primary sleep disorder * evidence of arousing periodic limb movements during titration * contraindications as listed on product labeling * pregnant * currently diagnosed with depression if symptomatic * deemed medically unsuitable by investigator * evidence of any type of infection or treatment of an infectious condition during the period of research participation * have a bi-level requirement, or prescribed a bi-level therapy device * cpap pressure \>15cmh2o * subjects with tracheotomy * uncontrolled hypertension * require supplemental oxygen * stimulants, major tranquillizers or antipsychotics * restless leg syndrome or periodic leg movement index of \> 5 per hour
xueshuantong injection (lyophilized) in the prevention of venous thromboembolism (vte) in hospitalized patients

Conditions: Venous Thromboembolism (VTE); Thromboembolism

Summary: the purpose of this study is to explore the efficacy, safety and cost-effectiveness of xueshuantong (lyophilized) for the prevention of venous thromboembolism (vte) in patients at risk of bleeding.

this is a non-randomized, observational study. this study primarily aims to investigate the efficacy, safety, and cost-effectiveness of using xueshuantong injection (lyophilized) for preventing venous thromboembolism (vte) in patients susceptible to bleeding. the subjects of the study comprise patients during the perioperative period (undergoing procedures lasting 45 minutes or longer), patients with a confirmed spontaneous cerebral hemorrhage (ich), and patients with a confirmed acute ischemic stroke (ais). additional objectives of this study including: 1. to evaluate the possible dose-dependency of xueshuantong injection (lyophilized); 2. to evaluate the impact in coagulation function after administration of xueshuantong injection (lyophilized)

Eligibility criteria:
inclusion criteria: * men or women of ≥18 year old; * hospitalized between jan 1, 2016 and aug. 1, 2023; * received intravenous (iv) xueshuantong (lyophilized) for ≥3 days; * who also meet one of the following criteria: 1. perioperative patients: performed any of the following surgical procedures (≥ 45 minutes in duration) during hospitalization- general surgery, orthopedic surgery, obstetrics and gynecology surgery, neurosurgery, urology surgery, cardiothoracic surgery, obesity surgery or cancer surgery; 2. hospitalization due to acute spontaneous cerebral hemorrhage: diagnosed as cerebral hemorrhage (acute/subacute), or subarachnoid hemorrhage, with clinical manifestations such as conscious disturbance, dyskinesia, or sensory dysfunction. presence of cerebral hemorrhage was confirmed by imaging; 3. hospitalization due to acute ischemic stroke: diagnosed as ischemic stroke, ischemic stroke (acute/subacute), cerebral infarction, or cerebral infarction (acute/subacute), acute stage or subacute stage of ischemic stroke, with clinical manifestations such as disturbance of consciousness, motor dysfunction, or sensory dysfunction. presence of cerebral hemorrhage was confirmed by imaging. exclusion criteria: * received any traditional chinese medicine (tcm) that contains total saponins of panax notoginseseng (pns) other than xueshuantong (lyophilized); * females who are pregnant or breast-feeding; * diagnosed venous thromboembolism occurred before enrollment; * received intravenous thrombolytic therapy for other reasons during hospitalization; * received prophylactic or therapeutic doses of anticoagulants after major surgery; * placed vena cava filters for vte prophylaxis before surgery; * received therapeutic dose of anticoagulants during the patient's hospital stay (ais patients);
in-vitro studies in depletion of haplotype mismatched alloreactive t cells

Conditions: Hematologic Malignancies; Hematopoietic Stem Cell Transplantation

Summary: the doctors in the bone marrow transplant service at the indiana university cancer center are working to better understand how the immune cells that cause graft-versus-host disease (a major complication of stem cell transplantation in which the donor immune cells attack the patient's organs) can be selectively removed from the graft, leaving other immune cells that fight infections.

the purpose of this research is to study how immune cells (called t cells) that cause graft-versus-host disease (gvhd) can best be selectively separated from other t cells and removed from the cells that will be returned to the cancer patient's body. these other t cells may protect against infection when given to patients after a stem cell transplant. the removal of cells that cause gvhd would allow doctors to safely give back the t cells that protect against infection, without the risk of gvhd.

Eligibility criteria:
inclusion criteria: * patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants will be eligible, if: (1)they have no circulating neoplastic cells in the peripheral blood as assessed by routine morphology or flow cytometry. (2)patients with acute myeloid or lymphocytic leukemia are in complete remission * first-degree relatives of patients evaluated for stem cell transplantation will be eligible if: (1) willing to undergo testing for hiv and hepatitis b and c (free of charge) (2) not pregnant at time of collection of blood (3)in good general health (4) no prior history of malignancy. (5) age 18 years or older if donating apheresis product. (because of the relatively invasive nature of the leukopheresis procedure and difficulties in obtaining consent, children \<18 who are first degree relatives of the patient will not undergo apheresis for studies on this protocol) * written informed consent exclusion criteria: -
left atrial imaging prior to cardioversion: leveraging computed tomography to rule out thrombus

Conditions: Atrial Fibrillation

Summary: evaluating contrast enhanced ecg-gated cardiac ct (cct) as an alternative to transesophageal echocardiography (tee) to expedite cardioversion of atrial fibrillation (af), improve patient care and reduce hospital admissions for af and atrial flutter.


Eligibility criteria:
inclusion criteria: 1. admitted patients who require la imaging prior to cardioversion 2. age ≥18 years old 3. able and willing to comply with the study procedures exclusion criteria: 1. indication for acute cardioversion (e.g. hemodynamic instability, acute coronary syndrome (acs), or pulmonary edema) 2. unwillingness or inability to provide informed consent 3. contraindication to cardiac ct * severe renal insufficiency(gfr\< 45ml/min) * allergy to intravenous contrast agents * contraindications to radiation exposure (for example, pregnancy) * inability to perform 20-second breath-hold 4. contraindication to tee * unrepaired tracheoesophageal fistula * esophageal obstruction or stricture * perforated hollow viscus * poor airway control * severe respiratory depression * uncooperative, unsedated patient
omega-3, nigella sativa, indian costus, quinine, anise seed, deglycyrrhizinated licorice, artemisinin, febrifugine on immunity of patients with (covid-19)

Conditions: Covid19; Immunodeficiency

Summary: the first version of this preprint article is registered on the 4th of may 2020 under the digital object identifier of:10.31219/osf.io/u56fc. covid-19 infections virus spread worldwide and impact many countries with sever economical sequences. the effective antiviral medication or vaccination for the virus is unavailable until the present date and it takes months or years to discover the effective treatment or test the efficacy of the discovered treatment. based on these facts, the human immune system against the virus may have an effective role to regulate the infection and reduce the mortality rate among the infected patients. this proposed research article aims to explore the available medication/ natural supplementation to boost the immunity system of the patients against covid-19 infections and reduce the mortality rate among infected patients. methods: a proposed clinical trial will be carried out to investigate the effect of the different treatment modalities on the human immune system against covid-19 infection.

natural supplementations have many reported effects on the human health ranged from immunity boosting to effective antiviral effect. omeg-3 as an example affect the human health by many mechanisms e.g. anti-oxidant, immunity boosting agent. moreover, omega-3 exerts an antiviral effect on flu virus by inhibiting influenza virus replication 1. on the other hand, black seed supplementation exerts a chelation effect on sickle cell anemia patients and inhibits human heme metabolism 2. moreover, black seed exerts an antiviral effect on the replication of old coronavirus and the expression of (trp-genes) family 3. in addition, omega-3 regulates the human immunity against bacterial and viral infections 4. during the past years, many natural sources exerts an antimalarial effect with perfect reported results 5.

Eligibility criteria:
inclusion criteria: * symptomatic with respiratory or systemic symptoms * positive nasopharyngeal swab for covid-19 * ct imaging showing viral pneumonia * temperature 38°c * respiratory rate \< 25 /min * oxygen saturation (pulse oximetry) \>95% exclusion criteria: * pregnant or breast feeding * hepatic failure child-pugh c * negative swab test of (sars)-(cov-2) * expected life is less than 24 hours * end-stage lung disease

Keywords: covid-19 omega3 thymoquinone
establishment and validation of early-warning model of perioperative pain for the elders

Conditions: Postoperative Pain; Pain Assessment; Elderly; Model

Summary: this study will collect perioperative pain-related data of elderly patients in multi-centers. analyzing these collected data to find the high-risk factors of postoperative pain in elderly patients and to establish an early-warning model of perioperative pain in elderly patients, so as to improve the ability of assessing the risks of postoperative pain in elderly patients and providing an early warning.

this study will collect perioperative pain-related data of elderly patients in multi-centers, including: preoperative general data, intraoperative anesthesia and surgical data, clinical laboratory data, postoperative pain and intervention, postoperative complications and quality of life. analyzing these collected data to find the high-risk factors of postoperative pain in elderly patients and to establish an early-warning model of perioperative pain in elderly patients, so as to improve the ability of assessing the risks of postoperative pain in elderly patients and providing an early warning.

Eligibility criteria:
inclusion criteria: * 18 years or older * undergoing general or regional anesthesia * hospitalized for at least 24 hours after surgery * able to give informed consent * able to read and write exclusion criteria: * existing diagnoses of psychiatric or neurologic pathology * a history of substance abuse * admitted to icu after surgery * patients with advanced tumors who have received preoperative chemotherapy or who are expected to receive postoperative chemotherapy.